Bharat Heavy Electricals Ltd (BHEL), Ranbaxy Laboratories Ltd, Council of Scientific and Industrial Research (CSIR) and National Institute of Immunology (NII) have been awarded for their innovation in research and development in India.
BHEL bagged the award for hi-tech corporate category while CSIR won the hi-tech academic award. NII and Ranbaxy Laboratories Ltd won pharma academic and pharma corporate awards respectively.
"The results of this (focus on excellence in research to drive innovations) have been striking, with a number of patents, technology transfers, public-private partnerships and consultancies for NII," said NII director Avadhesha Surolia at the Thomson Reuters Innovation Award ceremony jointly organised by Thomson Reuters and the Confederation of Indian Industry (CII).
All enterprises headquartered in India are considered for the award. The recipients were selected by analysing their innovation patented technology as recorded in Thomson Reuters patent information services.
The criteria included the number and impact of patents, the efficiency and effectiveness of research and the impact of innovation as measured by patent citations.
"In India, we finally recognise that we need to innovate and innovate fast," said National Knowledge Commission chairman Sam Pitroda, while handing over the awards to the winners.